Skin Tumors Induced by Sorafenib; Paradoxic RAS–RAF Pathway Activation and Oncogenic Mutations of HRAS , TP53 , and TGFBR1

J.-P. Arnault(Centre National de la Recherche Scientifique), Caroline Robert(Centre National de la Recherche Scientifique)

Clinical Cancer Research

November 17, 2011

Cited by 120

|New England Journal of Medicine|2015|5.8k

|New England Journal of Medicine|2018|1.8k

|JAMA|2016|1.1k

|Journal of Clinical Oncology|2017|480

|The Oncologist|2009|123

Skin Tumors Induced by Sorafenib; Paradoxic RAS–RAF Pathway Activation and Oncogenic Mutations of <i>HRAS</i> , <i>TP53</i> , and <i>TGFBR1</i>